標題
返回
確定
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
NMPA
#
NMPA
About 9 search results
Sort by Date
Business
PR Newswire
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
SHANGHAI
PR Newswire
2026-06-26 10:08
LEROCHOL
lerodalcibep
Everest Medicines
Business
PR Newswire
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
SHANGHAI
PR Newswire
2026-06-24 08:00
6MW5311
Mabwell
LILRB4/CD3
Business
PR Newswire
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI
PR Newswire
2026-06-22 19:33
Satri-cel
CAR T-cell therapy
Solid Tumors
Business
PR Newswire
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG
PR Newswire
2026-06-12 09:57
Gumokimab
AK111
Akeso
Business
PR Newswire
Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI
PR Newswire
2026-06-10 12:06
Harbour BioMed
HBM7004
NMPA
Business
PR Newswire
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG
PR Newswire
2026-06-10 09:00
Antengene
ATG-201
CD19 x CD3
Business
PR Newswire
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
SHANGHAI
PR Newswire
2026-06-05 11:30
9MW5211
Mabwell
Inflammatory Bowel Disease
Business
PR Newswire
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
SAN FRANCISCO and SUZHOU, China
PR Newswire
2026-06-04 16:35
Innovent Biologics
arcotatug tavatecan
IBI343
Business
PR Newswire
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
GUANGZHOU, China
PR Newswire
2026-06-04 16:19
Rocbrutinib
Lupeng Pharmaceutical
BTK inhibitor